Predicting Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC).*
In yesterday's post I wrote about the possibility of looking for the presence of the splice variant ARV7 to determine if you would be resistant to enzalutamide (Xtandi). Today I am going to expand on [...]
Understanding and Predicting Initial Resistance to Enzalutimide (Xtandi) by Evaluating the Presence of ARV7 *
I have written a lot about how we need more data about the many new drugs we have to treat men with advanced prostate cancer. The many questions that continue to swirl around us pertain [...]
Anticoagulants May Increase Survival in Men with Advanced Prostate Cancer Taking Chemotherapy*
Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of [...]
Ten minute anonymous survey about Life With Prostate Cancer
Please take the ten minute anonymous survey about Life With Prostate Cancer. Go to: How We Live With Prostate Cancer Survey The direct link to the survey is: https://www.surveymonkey.com/s/livingwithprostatecancer The results will be used to [...]
PSA Decline is a Potential Biomarker for Identifying Early Resistance to Zytiga and Xtandi In Men Who are Post Chemotherapy*
Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents. They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). [...]
Defaulting Cancer Treatment Is Associated with Psychological Distress and A Desire for Psychological Support*
Sometimes some of us just simply decide that we will not start any treatment or continue a treatment protocol simply because we don’t want to have treatment. This type of decision is different from our [...]